340B drug discounts are drifting from patients to profit, and reform is now on the table

medicalxpress - The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking behaviors, says the American College of Physicians (ACP). In a new policy, "Reforming 340B to Promote Program Integrity and Better Serv…

AI Summary: The 340B drug-discount program is under renewed scrutiny after analyses and advocacy groups argue discounts intended to help patients are instead boosting institutional margins. Hospitals, provider groups and the AHA are contesting HRSA proposals and court rulings, sparking policy debates and potential regulatory fixes to curb markups and steer savings back to vulnerable patients.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

AbbVie sues HHS over 340B patient definition and guidance / 7 wks

Bill would let patient drug spending count toward insurance deductibles / 6 wks

Hospitals push regulators to block expanded 340B claims reporting requirements / 2 months

131 hospitals sue HHS over alleged Disproportionate Share underpayments / 1 month

Senate Democrats unveil plan to cut health costs and expand coverage / 2 months

Optum Rx/Caremark and FTC edge toward settlement in insulin case / 2 months

Nearly 10% of surgeons exit clinical practice within eight years / 8 days